Cue Biopharma (CUE) Change in Accured Expenses (2017 - 2025)

Cue Biopharma has reported Change in Accured Expenses for 9 years, with the latest figure at -$259000.0 in Q4 2025.

• Quarterly Change in Accured Expenses rose 11.0% year-over-year to -$259000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$1.3 million (down 5.53% YoY) and the FY2025 annual result came in at -$1.3 million, down 5.53% from the prior year.
• Change in Accured Expenses retreated to -$259000.0 in Q4 2025 per CUE's latest filing, from $352000.0 in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $2.0 million in Q3 2021 and troughed at -$2.7 million in Q2 2025.
• A 5-year average of -$58812.4 and a median of -$116000.0 in 2021 frame the typical range for Change in Accured Expenses.
• The sharpest annual moves came in 2023 and 2025: Change in Accured Expenses soared 703.92% in 2023, then tumbled 320.47% in 2025.
• Over 5 years, Change in Accured Expenses stood at $630752.0 in 2021, then slumped by 152.32% to -$330000.0 in 2022, then sank by 198.48% to -$985000.0 in 2023, then soared by 70.46% to -$291000.0 in 2024, then advanced by 11.0% to -$259000.0 in 2025.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered -$259000.0, $352000.0, and -$2.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.